Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis

Charlotta Preger¹, Maria Aspenberg¹, Metta Berenpas¹, Armita Dwivedi², Juliana Bordignon Draibe³, Peter Nilsson¹, Mark A. Little² and Elisa Pin¹, ¹Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, ²Trinity Kidney Centre, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland, ³Department of Nephrology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Autoantibody(ies), autoantigens, Disease Activity, Vasculitis

Session Information

Date: Monday, October 27, 2025

Title: (0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: ANCA-associated vasculitides (AAV) are a heterogenous group systemic autoimmune diseases characterized by necrotizing inflammation of small blood vessels requiring prompt initiation of immunosuppressive treatment to limit organ damage. Autoantibodies are the hallmark of AAV and is used in the clinic for diagnosis and classification. In addition, the pathogenic role of these autoantibodies has previously been suggested, and autoantibodies might therefore be used as biomarkers for disease activity.As part of the PersonAlisation of RelApse risk in autoimmune DISEase (PARADISE) consortium, we aimed to investigate novel, and previously known autoantibodies in AAV to be used as biomarkers for disease activity.

Methods: Plasma samples (n=1221) from 535 individuals with AAV, and 66 healthy controls, as well as clinical information were collected from the RITA-Ireland Vasculitis Biobank, a national cohort across eight sites in Ireland. Samples were screened for IgG autoantibodies using our in-house multiplex antigen bead array including 369 antigens corresponding to 272 proteins.

Results: Novel autoantibodies with higher prevalence in the AAV group compared to healthy controls were identified. In addition, we could confirm autoantibody reactivities found in another independent cohort in previous studies by our group. Of the previously known anti-MPO positive individuals, we could confirm 98% of these, indicating that our assay is robust. Finally, the profiling of autoantibodies in samples collected from AAV patients at active disease versus remission also revealed a preliminary association of specific autoantibodies.

Conclusion: The autoantibody profiling in this study identified several novel autoantibodies, and the possible association with disease activity. Further analysis of the clinical impact of these findings still needs to be determined.

Disclosures: C. Preger: None; M. Aspenberg: None; M. Berenpas: None; A. Dwivedi: None; J. Bordignon Draibe: None; P. Nilsson: None; M. Little: None; E. Pin: None.

To cite this abstract in AMA style:

Preger C, Aspenberg M, Berenpas M, Dwivedi A, Bordignon Draibe J, Nilsson P, Little M, Pin E. Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/profiling-of-novel-autoantibodies-for-prediction-of-disease-activity-in-anca-associated-vasculitis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/profiling-of-novel-autoantibodies-for-prediction-of-disease-activity-in-anca-associated-vasculitis/